Abstract AIM: To evaluate prospectively the clinical efficacy and safety of endoscopic hydrostatic balloon dilation in a consecutive cohort of symptomatic intestinal Crohn's disease strictures. METHODS: Between September 2003 and December 2008 we performed endoscopic balloon dilations in 37 Crohn's disease patients with 39 intestinal symptomatic strictures (4 naïve and 35 postoperative). Dilations were performed using a Rigiflex through-the-scope balloon. Clinical success rate was claimed if a patient remained asymptomatic and did not require surgery or further endoscopic dilation, following technical success. Actuarial curves of clinical, endoscopic (redilation) and surgical recurrence were obtained by Kaplan-Meier method. Demographic and disease variables were related to the main outcomes. RESULTS: After a mean follow-up of 26.3 months (range, 2-61 months), the long-term global benefit rate was 89% (33/37). The 1-2-3 years cumulative symptom-free rates were respectively: 76%, 55% and 46%. Four patients were operated upon. Technical success predicts a lower rate of surgery. There were no complications related to the endoscopic procedures. CONCLUSIONS: Endoscopic balloon dilation of symptomatic Crohn's disease strictures may achieve clinical benefit in many patients and is a valid alternative to surgery in the management of the disease. Dilation may be repeated in recurrent intestinal obstructions and appears safe without morbidity.

Scimeca D, Mocciaro F, Cottone M, Montalbano LM, D'Amico G, Olivo M, et al. (2011). Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures. DIGESTIVE AND LIVER DISEASE, 43(2), 121-125 [10.1016/j.dld.2010.05.001].

Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures.

COTTONE, Mario;
2011-01-01

Abstract

Abstract AIM: To evaluate prospectively the clinical efficacy and safety of endoscopic hydrostatic balloon dilation in a consecutive cohort of symptomatic intestinal Crohn's disease strictures. METHODS: Between September 2003 and December 2008 we performed endoscopic balloon dilations in 37 Crohn's disease patients with 39 intestinal symptomatic strictures (4 naïve and 35 postoperative). Dilations were performed using a Rigiflex through-the-scope balloon. Clinical success rate was claimed if a patient remained asymptomatic and did not require surgery or further endoscopic dilation, following technical success. Actuarial curves of clinical, endoscopic (redilation) and surgical recurrence were obtained by Kaplan-Meier method. Demographic and disease variables were related to the main outcomes. RESULTS: After a mean follow-up of 26.3 months (range, 2-61 months), the long-term global benefit rate was 89% (33/37). The 1-2-3 years cumulative symptom-free rates were respectively: 76%, 55% and 46%. Four patients were operated upon. Technical success predicts a lower rate of surgery. There were no complications related to the endoscopic procedures. CONCLUSIONS: Endoscopic balloon dilation of symptomatic Crohn's disease strictures may achieve clinical benefit in many patients and is a valid alternative to surgery in the management of the disease. Dilation may be repeated in recurrent intestinal obstructions and appears safe without morbidity.
2011
Settore MED/09 - Medicina Interna
Scimeca D, Mocciaro F, Cottone M, Montalbano LM, D'Amico G, Olivo M, et al. (2011). Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures. DIGESTIVE AND LIVER DISEASE, 43(2), 121-125 [10.1016/j.dld.2010.05.001].
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1590865810001659-main.pdf

Solo gestori archvio

Descrizione: Articolo versione editoriale
Dimensione 226.44 kB
Formato Adobe PDF
226.44 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/53765
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 75
  • ???jsp.display-item.citation.isi??? 64
social impact